Work

Actr-47. Tpi 287, a Brain Penetrable Anti-microtubule Agent, Plus Bevacizumab in Patients With Recurrent Glioblastoma: Results From a Dose Escalation Phase 1/2 Clinical Trial

Year: 2016

Type: conference-abstract

Source: Neuro-Oncology

DOI: 10.1093/neuonc/now212.045

Authors: Samuel Goldlust, Burt Nabors, J. Paul Duic, Nimish Mohile, Tara Benkers, Sigmund Hsu, Sandra Silberman, Samuel Singer, Mayank Rao, George Farmer

Institutions: University of Alabama at Birmingham, Neurological Surgery, University of Rochester, Swedish Medical Center, The University of Texas Health Science Center at Houston, Cortice Biosciences, Inc. (United States)

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2587649596

Cites:

Cited by:

Related to: 10